Used in conjunction with the company’s proprietary CellOptics platform, a robotic microscopy system, oncoFISH cervical provides the physician, while still adhering to current practice guidelines, with an assessment of risk of progression of low grade dysplasia to cancer of the cervix.
oncoFISH cervical will be offered as a laboratory developed test through Ikonisys’s licensed CAP-accredited clinical laboratory. Through its CellOptics platform, Ikonisys is developing a stream of proprietary and non-proprietary tests based on the detection of rare cells in a practical, efficient and economical manner.
In addition to simply presenting cell images to the laboratory technologist, the platform analyzes the cells, offering an interpretation, while simultaneously allowing the pathologist to concur or override the analysis. Ikonisys will be initiating clinical trials on oncoFISH cervical for FDA clearance.
Petros Tsipouras, CEO and chairman of Ikonisys, said: “Through our novel tests and unique ability to provide intelligent, digital pathology, Ikonisys is undoubtedly advancing the practice of medicine. Not only are we providing patients and physicians early and accurate detection, but we’re helping them to realize the promise of personalized medicine by enabling practitioners to provide the appropriate treatment based on individual risk.”